Product Data Sheet
Product Name:
CAS No.:
Cat. No.:
MWt:
Formula:
Purity :Moexipril hydrochloride82586-52-5HY-B0378A535.03C27H35ClN2O7>98%
Solubility:DMSO 20 mg/mL; Water <1 mg/mL
Mechanisms:
Pathways:Metabolism/Protease; Target:ACE
Biological Activity:
Moexipril HCl is a potent orally active non-sulfhydryl angiotensin converting enzyme(ACE) inhibitor,MoexiprilHClisapotentorallyactivenonsulfhydrylangiotensinconvertingenzyme(ACE)inhibitorwhich is used for the treatment of hypertension and congestive heart failure.
Target: ACE
Moexipril is a long-acting ACE inhibitor suitable for once-daily administration, and like some ACEinhibitors, moexipril is a prodrug and needs to be hydrolyzed in the liver into its active carboxylicmetabolite, moexiprilat, to become effective [1]. Upon oral administration of moexipril (10
mg/kg/day) to spontaneously hypertensive rats, plasma angiotensin II concentration decreased toundetectable levels, plasma ACE activity was inhibited by 98% and plasma angiotensin I
concentration increased 8.6-fold 1 h after dosing. At 24 h, plasma angiotensin I and angiotensin IIconcentrations had returned to pretreatment levels, whereas plasma ACE activity was still inhibitedby 56%. Four-...
References:
[1]. Chrysant, S.G. and G.S. Chrysant, Pharmacological and clinical profile of moexipril: a concisereview. J Clin Pharmacol, 2004. 44(8): p. 827-36.
[2]. Edling, O., et al., Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor:
pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther, 1995.275(2): p. 854-63.
[3]. Song, J.C. and C.M. White, Clinical pharmacokinetics and selective pharmacodynamics of newangiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet, 2002. 41(3): p. 207-24.
Caution: Not fully tested. For research purposes only
Medchemexpress LLC
http://
18 Wilkinson Way, Princeton, NJ 08540,USA
http:// Web: http://Email: info@medchemexpr
